Enzalutamide is being evaluated across numerous Phase I, II, and III clinical trials focusing on prostate cancer—including metastatic castration-resistant, castration-sensitive, and locally advanced carcinomas—and advanced breast cancer subtypes. Sponsored by academic medical centers and pharmaceutical companies, these trials encompass active recruitment, completed, and not yet recruiting statuses. Specific investigations evaluate enzalutamide combination therapies for PET-positive recurrent prostate cancer and docetaxel addition in metastatic disease.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06991556 | ACTIVE_NOT_RECRUITING | Metastatic Hormone-sensitive Prostate Cancer |
Novartis Pharmaceuticals |
2025-07-07 | PHASE2 |
| NCT06922318 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2025-08-19 | PHASE2 |
| NCT07711002 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
AstraZeneca |
2026-10-01 | PHASE3 |
| NCT05367440 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
AstraZeneca |
2022-06-02 | PHASE1; PHASE2 |
| NCT06863272 | RECRUITING | Castration-Resistant Prostatic Cancer; Metastasis |
Merck Sharp & Dohme LLC |
2025-07-03 | PHASE1; PHASE2 |
| NCT06592924 | RECRUITING | Prostate Cancer (Adenocarcinoma) |
Canadian Cancer Trials Group |
2025-05-28 | PHASE3 |
| NCT06378866 | RECRUITING | Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma |
Mayo Clinic |
2024-06-03 | PHASE2 |
| NCT06499870 | RECRUITING | Prostate Adenocarcinoma |
Sean Sachdev |
2024-09-06 | PHASE2 |
| NCT07782112 | NOT_YET_RECRUITING | Prostatic Neoplasms; Biochemical Recurrence; Oligometastatic Prostate Cancer |
Ente Ospedaliero Cantonale, Bellinzona |
2026-11 | PHASE3 |
| NCT07570979 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Novartis Pharmaceuticals |
2026-05-25 | PHASE1 |
| NCT07620574 | ENROLLING_BY_INVITATION | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer |
Exelixis |
2026-07-30 | PHASE3 |
| NCT06632977 | RECRUITING | Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2025-02-06 | PHASE2 |
| NCT04221542 | RECRUITING | Prostate Cancer |
Amgen |
2020-03-04 | PHASE1 |
| NCT04104776 | RECRUITING | Advanced Solid Tumor; Diffuse Large B Cell Lymphoma; Lymphoma, T-Cell; Mesothelioma, Malignant; Prostatic Neoplasms, Castration-Resistant; Endometrial Cancer; Ovarian Clear Cell Carcinoma; Metastatic Castration-resistant Prostate Cancer |
Novartis Pharmaceuticals |
2019-09-18 | PHASE1; PHASE2 |
| NCT07802704 | NOT_YET_RECRUITING | Neoplasms, Prostate |
GlaxoSmithKline |
2026-09-22 | PHASE3 |
| NCT03899155 | RECRUITING | Cancer |
Bristol-Myers Squibb |
2019-08-09 | PHASE2 |
| NCT07751133 | RECRUITING | Prostate Cancer; mHSPC; mCRPC |
University College, London |
2026-08-28 | PHASE3 |
| NCT02960022 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2016-12-22 | PHASE2 |
| NCT07611110 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2026-05-04 | PHASE3 |
| NCT04729114 | RECRUITING | Prostate Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2021-06-14 | PHASE1 |
| NCT07592910 | NOT_YET_RECRUITING | Metastatic Castrate Resistant Prostate Cancer (mCRPC); Prostate Cancer (Adenocarcinoma) |
Prostate Cancer Clinical Trials Consortium |
2026-08 | PHASE2 |
| NCT06844383 | RECRUITING | Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer) |
Prostate Cancer Clinical Trials Consortium |
2026-05-04 | PHASE2 |
| NCT06691984 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Amgen |
2024-12-09 | PHASE3 |
| NCT06130995 | RECRUITING | Androgen Deprivation Therapy; Locally Advanced Prostate Cancer |
University of Oklahoma |
2024-12-26 | PHASE1 |
| NCT07730580 | NOT_YET_RECRUITING | Advanced Prostate Cancer |
Evopoint Biosciences Inc. |
2026-07-13 | PHASE2 |
| NCT06096870 | RECRUITING | Prostate Cancer; Recurrent Prostate Cancer; PET Positive |
National Cancer Institute (NCI) |
2024-04-22 | PHASE2 |
| NCT06257693 | RECRUITING | Prostate Adenocarcinoma |
Alessa Therapeutics Inc. |
2024-06-21 | PHASE1 |
| NCT07230106 | RECRUITING | Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-12-08 | PHASE2 |
| NCT07028853 | RECRUITING | Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate |
Pfizer |
2025-09-28 | PHASE3 |
| NCT06136624 | RECRUITING | Prostate Cancer Metastatic |
Merck Sharp & Dohme LLC |
2023-12-31 | PHASE3 |
| NCT07226986 | RECRUITING | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy |
Novartis Pharmaceuticals |
2025-12-05 | PHASE1; PHASE2 |
| NCT03768063 | ACTIVE_NOT_RECRUITING | Cancer |
Hoffmann-La Roche |
2019-02-28 | PHASE3 |
| NCT06616155 | RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 |
University of Michigan Rogel Cancer Center |
2026-06 | PHASE1; PHASE2 |
| NCT04471974 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
Rahul Aggarwal |
2021-01-26 | PHASE2 |
| NCT06136650 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms |
Merck Sharp & Dohme LLC |
2023-12-18 | PHASE3 |
| NCT07795177 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer |
Anhui Medical University |
2026-10-01 | PHASE2 |
| NCT03460977 | RECRUITING | Metastatic Castration Resistant Prostate Cancer (mCRPC); Small Cell Lung Cancer (SCLC); Follicular Lymphoma (FL) |
Pfizer |
2018-04-17 | PHASE1 |
| NCT07287150 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Hoffmann-La Roche |
2026-03-11 | PHASE2 |
| NCT07723248 | RECRUITING | Metastatic Castration Resistant Prostate Cancer |
ORIC Pharmaceuticals |
2026-08-03 | PHASE3 |
| NCT05422911 | RECRUITING | Metastatic Cancer; Neoplasm, Prostate; Castrate-sensitive; Castrate-sensitive Prostate Cancer |
Sun Pharmaceutical Industries Limited |
2022-08-31 | PHASE2 |
| NCT04145375 | ENROLLING_BY_INVITATION | mCRPC |
Zenith Epigenetics |
2019-11-12 | PHASE1; PHASE2 |
| NCT05914116 | RECRUITING | Advanced Solid Tumors |
DualityBio Inc. |
2023-08-17 | PHASE1; PHASE2 |
| NCT07311694 | RECRUITING | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2026-02-02 | PHASE3 |
| NCT06520345 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Telix Pharmaceuticals (Innovations) Pty Limited |
2024-07-26 | PHASE3 |
| NCT05393791 | RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Leiden University Medical Center |
2022-11-10 | PHASE2 |
| NCT02861573 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Merck Sharp & Dohme LLC |
2016-11-17 | PHASE1; PHASE2 |
| NCT05726292 | RECRUITING | Prostate Cancer; Prostate Adenocarcinoma |
University of Chicago |
2025-01-06 | PHASE2 |
| NCT07104110 | NOT_YET_RECRUITING | Prostatic Neoplasms |
Qilu Pharmaceutical Co., Ltd. |
2025-10 | PHASE1; PHASE2 |
| NCT06099769 | RECRUITING | Metastatic Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2023-10-18 | PHASE2 |
| NCT06120491 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Sensitive Prostate Cancer |
AstraZeneca |
2023-11-21 | PHASE3 |
| NCT06764485 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Celgene |
2025-03-13 | PHASE3 |
| NCT07683013 | NOT_YET_RECRUITING | Castration-Resistant Prostate Cancer (CRPC) |
Hyundai Bioscience Co., Ltd. |
2026-07 | PHASE1 |
| NCT05818683 | RECRUITING | Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer |
Janssen Research & Development, LLC |
2023-04-26 | PHASE1 |
| NCT05011188 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer; Prostate Cancer |
Rahul Aggarwal |
2022-01-19 | PHASE1; PHASE2 |
| NCT07512076 | NOT_YET_RECRUITING | Prostate Cancer Patients; Elderly Patients; Pharmacokinetic Study |
Sunnybrook Health Sciences Centre |
2026-04 | PHASE2 |
| NCT04363164 | RECRUITING | Castration Resistant Metastatic Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-08-19 | PHASE2 |
| NCT05112965 | ACTIVE_NOT_RECRUITING | Neoplasms |
Hoffmann-La Roche |
2021-12-01 | PHASE3 |
| NCT06228053 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Syntrix Biosystems, Inc. |
2024-11-18 | PHASE2 |
| NCT06576037 | RECRUITING | Solid Tumor |
M.D. Anderson Cancer Center |
2024-10-31 | PHASE1 |
| NCT06457919 | RECRUITING | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2024-06-04 | PHASE1; PHASE2 |
| NCT05413421 | RECRUITING | Metastatic Prostate Cancer |
ORIC Pharmaceuticals |
2022-06-01 | PHASE1 |
| NCT02750358 | ACTIVE_NOT_RECRUITING | Breast Cancer; Early Stage; Triple Negative Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2016-05-19 | PHASE2 |
| NCT07783282 | NOT_YET_RECRUITING | Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2026-08-31 | PHASE1 |
| NCT02685397 | ACTIVE_NOT_RECRUITING | Castration-resistant Prostate Cancer Patients with Oligometastases |
Sir Mortimer B. Davis - Jewish General Hospital |
2016-10 | PHASE2; PHASE3 |
| NCT06236139 | RECRUITING | Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 |
Fred Hutchinson Cancer Center |
2024-11-26 | PHASE1; PHASE2 |
| NCT04455750 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2021-10-14 | PHASE3 |
| NCT07241416 | RECRUITING | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) |
Jiangsu HengRui Medicine Co., Ltd. |
2025-12-05 | PHASE3 |
| NCT05743621 | RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Weill Medical College of Cornell University |
2023-11-20 | PHASE1 |
| NCT06059118 | RECRUITING | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2023-10-04 | PHASE2 |
| NCT02446405 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms |
University of Sydney |
2014-03 | PHASE3 |
| NCT03344211 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer |
University of Southern California |
2018-11-21 | PHASE2 |
| NCT05873192 | RECRUITING | Prostate Cancer |
M.D. Anderson Cancer Center |
2025-06-03 | PHASE2 |
| NCT05406999 | RECRUITING | Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer; Intense Endocrine Therapy |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2020-02-01 | PHASE2 |
| NCT06551324 | ACTIVE_NOT_RECRUITING | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
Pfizer |
2024-10-21 | PHASE3 |
| NCT06629779 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Pfizer |
2024-10-22 | PHASE3 |
| NCT07198633 | RECRUITING | Advanced Prostate Cancer |
Qilu Pharmaceutical Co., Ltd. |
2025-11-05 | PHASE1; PHASE2 |
| NCT03903835 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Karolinska Institutet |
2019-02-01 | PHASE3 |
| NCT04986423 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Zenith Epigenetics |
2021-09-08 | PHASE2 |
| NCT07104643 | NOT_YET_RECRUITING | mCRPC |
TYK Medicines, Inc |
2025-08 | PHASE1; PHASE2 |
| NCT06894511 | ACTIVE_NOT_RECRUITING | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Novartis Pharmaceuticals |
2025-09-11 | PHASE2 |
| NCT04787744 | RECRUITING | Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer |
VA Office of Research and Development |
2021-07-01 | PHASE2; PHASE3 |
| NCT04557449 | ACTIVE_NOT_RECRUITING | Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung |
Pfizer |
2020-09-23 | PHASE2 |
| NCT05942001 | RECRUITING | Advanced Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2023-08-03 | PHASE1 |
| NCT07277270 | RECRUITING | Neoplasms |
GlaxoSmithKline |
2025-12-03 | PHASE1 |
| NCT05751941 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Metastatic Prostate Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2023-02-14 | PHASE2 |
| NCT06126731 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Institute of Cancer Research, United Kingdom |
2023-11-02 | PHASE1; PHASE2 |
| NCT02446444 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms |
University of Sydney |
2014-03 | PHASE3 |
| NCT06332170 | RECRUITING | Advanced Solid Tumor |
Hansoh BioMedical R&D Company |
2024-04-26 | PHASE1 |
| NCT06702995 | RECRUITING | Metastatic Castrate-Resistant Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer) |
Evopoint Biosciences Inc. |
2023-04-19 | PHASE1; PHASE2 |
| NCT03860987 | COMPLETED | Castrate Sensitive Prostate Cancer |
National Cancer Institute (NCI) |
2019-04-30 | PHASE2 |
| NCT04015622 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
British Columbia Cancer Agency |
2020-10-07 | PHASE2 |
| NCT00268476 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Medical Research Council |
2005-07-08 | PHASE2; PHASE3 |
| NCT04821622 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Pfizer |
2021-05-12 | PHASE3 |
| NCT06582628 | RECRUITING | Metastatic Prostate Cancer |
Fundacion Oncosur |
2024-07-05 | PHASE2 |
| NCT05539300 | UNKNOWN | Prostate Cancer |
UMC Utrecht |
2023-03-01 | |
| NCT05627752 | UNKNOWN | Prostate Cancer; Castrate Resistant Prostate Cancer |
Zhongnan Hospital |
2024-06-01 | PHASE2; PHASE3 |
| NCT02452008 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2016-05-03 | PHASE2 |
| NCT04655365 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
CHU de Quebec-Universite Laval |
2022-03-22 | PHASE2 |
| NCT05057013 | ACTIVE_NOT_RECRUITING | Bladder Cancer; Triple Negative Breast Cancer; Castration-resistant Prostate Cancer; Cervical Cancer; RAS Wild Type Colorectal Cancer; Endometrial Cancer; Gastric Cancer; Hepatocellular Carcinoma (HCC); Melanoma; Non-small Cell Lung Cancer (NSCLC); Oesophageal Cancer; Ovarian Cancer; Pancreatic Cancer; Squamous Cell Cancer of the Head and Neck |
Cancer Research UK |
2021-11-10 | PHASE1; PHASE2 |
| NCT06015321 | UNKNOWN | Prostatic Adenocarcinoma |
Samsung Medical Center |
2023-10-01 | PHASE2 |
| NCT05683964 | ACTIVE_NOT_RECRUITING | Prostate Adenocarcinoma; Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Beth Israel Deaconess Medical Center |
2023-01-19 | EARLY_PHASE1 |
| NCT04335682 | COMPLETED | Metastatic Prostate Cancer; Prostate Cancer Metastatic; Prostate Cancer; Castrate Resistant Prostate Cancer; Hormone Sensitive Prostate Cancer; Non-metastatic Prostate Cancer |
Alliance Foundation Trials, LLC. |
2021-08-17 | PHASE2 |
| NCT05081193 | COMPLETED | Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2022-03-07 | PHASE2 |
| NCT04262154 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2020-03-03 | PHASE2 |
| NCT03568656 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors |
CellCentric Ltd. |
2018-07-23 | PHASE1; PHASE2 |
| NCT05588609 | TERMINATED | NSCLC Harboring NRG1 Fusion; Metastatic Castration-resistant Prostate Cancer |
Partner Therapeutics, Inc. |
2022-11-17 | PHASE2 |
| NCT05733351 | TERMINATED | Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 |
Emory University |
2023-08-03 | PHASE1 |
| NCT04332744 | COMPLETED | Metastatic Prostate Cancer |
MedSIR |
2020-09-02 | PHASE2 |
| NCT05730712 | COMPLETED | Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 |
Mayo Clinic |
2024-03-08 | PHASE2 |
| NCT06505278 | UNKNOWN | Prostate Cancer |
Sun Yat-sen University |
2024-08 | PHASE2 |
| NCT06312670 | COMPLETED | Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma |
Pedro Barata, MD, MSc |
2024-05-16 | PHASE2 |
| NCT05191017 | WITHDRAWN | Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms |
Nuvation Bio Inc. |
2022-09 | PHASE1; PHASE2 |
| NCT03764540 | TERMINATED | Metastatic Prostate Cancer |
Centre hospitalier de l'Université de Montréal (CHUM) |
2019-04-01 | PHASE2 |
| NCT05037500 | TERMINATED | Castration-Resistant Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
Roswell Park Cancer Institute |
2022-01-26 | PHASE1 |
| NCT04179864 | TERMINATED | Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer |
Epizyme, Inc. |
2019-11-18 | PHASE1; PHASE2 |
| NCT05075577 | TERMINATED | Prostate Cancer |
ESSA Pharmaceuticals |
2021-12-21 | PHASE1; PHASE2 |
| NCT05457257 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2022-07-29 | PHASE4 |
| NCT02339168 | COMPLETED | Prostate Cancer |
University of California, Davis |
2016-06-22 | PHASE1 |
| NCT01990196 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Jonsson Comprehensive Cancer Center |
2014-09-23 | PHASE2 |
| NCT04381832 | COMPLETED | Prostatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resistant Prostatic Neoplasms; Prostatic Cancer, Castration-Resistant |
Arcus Biosciences, Inc. |
2020-07-07 | PHASE1; PHASE2 |
| NCT02312557 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostate Carcinoma; Hormone-Resistant Prostate Cancer; PSA Progression; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2014-11-18 | PHASE2 |
| NCT05526248 | COMPLETED | Biochemically Recurrent Prostate Cancer |
Bayer |
2022-12-19 | PHASE2 |
| NCT03734653 | COMPLETED | Prostate Cancer; Castration-Resistant Prostate Cancer |
University of Colorado, Denver |
2019-01-18 | EARLY_PHASE1 |
| NCT05204927 | ACTIVE_NOT_RECRUITING | Metastasis From Malignant Tumor of Prostate |
Curium US LLC |
2022-02-14 | PHASE3 |
| NCT06130995 | Not yet recruiting | Androgen Deprivation Therapy|Locally Advanced Prostate Cancer |
University of Oklahoma |
2024-08 | Phase 1 |
| NCT05252390 | TERMINATED | Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor |
Nuvation Bio Inc. |
2022-03-29 | PHASE1 |
| NCT05551117 | TERMINATED | Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma |
MacroGenics |
2023-06-13 | PHASE2 |
| NCT05339672 | Recruiting | Drug-drug Interaction |
Radboud University Medical Center|Astellas Pharma Inc |
2024-07-01 | -- |
| NCT03850795 | TERMINATED | Prostate Cancer Metastatic; Castration-resistant Prostate Cancer |
Hinova Pharmaceuticals USA, Inc. |
2021-03-15 | PHASE3 |
| NCT03674814 | COMPLETED | Prostate Cancer |
University of Chicago |
2018-10-23 | PHASE1 |
| NCT01885949 | TERMINATED | Prostate Cancer |
Massachusetts General Hospital |
2013-09-03 | PHASE2 |
| NCT04446117 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer; Prostate Adenocarcinoma |
Exelixis |
2020-10-19 | PHASE3 |
| NCT04419402 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
2020-08-17 | PHASE2 |
| NCT06096870 | Recruiting | Prostate Cancer|Recurrent Prostate Cancer|PET Positive |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2024-04-22 | Phase 2 |
| NCT03700099 | UNKNOWN | Prostate Cancer; Castration-resistant Prostate Cancer |
Instituto do Cancer do Estado de São Paulo |
2019-09-03 | PHASE2 |
| NCT02935205 | UNKNOWN | Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer |
Mamta Parikh |
2017-01-17 | PHASE1; PHASE2 |
| NCT03641560 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
Astellas Pharma Inc |
2018-09-19 | PHASE4 |
| NCT02194842 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2015-10 | PHASE3 |
| NCT05212857 | UNKNOWN | Prostate Cancer |
Fudan University |
2022-04 | PHASE2 |
| NCT03927391 | COMPLETED | Prostatic Neoplasms, Castration-Resistant |
Radboud University Medical Center |
2019-05-30 | PHASE4 |
| NCT03207529 | COMPLETED | Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Androgen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; PTEN Positive; Recurrent Breast Carcinoma; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma |
M.D. Anderson Cancer Center |
2019-06-07 | PHASE1 |
| NCT04139772 | UNKNOWN | Metastatic Castration-resistent Prostate Cancer |
National Cancer Institute, Naples |
2019-09-01 | PHASE3 |
| NCT02689427 | COMPLETED | Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma |
M.D. Anderson Cancer Center |
2016-09-22 | PHASE2 |
| NCT04647526 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company |
2021-02-25 | PHASE3 |
| NCT05743621 | Recruiting | Prostatic Neoplasms Castration-Resistant |
Weill Medical College of Cornell University|Sagimet Biosciences Inc. |
2023-11-20 | Phase 1 |
| NCT02213107 | COMPLETED | Prostate Cancer |
University of Rochester |
2014-09 | PHASE2 |
| NCT04631601 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Amgen |
2021-01-15 | PHASE1; PHASE2 |
| NCT04409288 | TERMINATED | Prostate Cancer |
Chinese University of Hong Kong |
2020-07-20 | PHASE3 |
| NCT04116775 | UNKNOWN | Prostate Cancer; Prostate Cancer Metastatic |
Julie Graff, MD |
2019-10-30 | PHASE2 |
| NCT02684227 | COMPLETED | Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 |
M.D. Anderson Cancer Center |
2016-08-24 | PHASE2 |
| NCT03939689 | COMPLETED | Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Prostatic Neoplasm; Cancer of the Prostate; Progressive mCRPC |
Progenics Pharmaceuticals, Inc. |
2019-05-30 | PHASE2 |
| NCT04207255 | COMPLETED | Prostate Cancer |
Medical University of South Carolina |
2020-03-27 | PHASE2 |
| NCT03275857 | COMPLETED | Prostate Cancer |
University of Rochester |
2018-09-21 | EARLY_PHASE1 |
| NCT04628988 | COMPLETED | Prostatic Neoplasms |
Celgene |
2021-07-28 | PHASE1 |
| NCT04844749 | TERMINATED | Metastatic Castration-resistant Prostate Cancer; Androgen Resistant Prostatic Cancer |
Veru Inc. |
2021-06-24 | PHASE3 |
| NCT03310541 | COMPLETED | Breast Cancer; Prostate Cancer; Advanced Solid Tumors |
Memorial Sloan Kettering Cancer Center |
2017-10-11 | PHASE1 |
| NCT03709550 | WITHDRAWN | Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Level Greater Than or Equal to Two; PSA Progression; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
Roswell Park Cancer Institute |
2021-04-15 | PHASE1; PHASE2 |
| NCT03809000 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
RTOG Foundation, Inc. |
2019-04-15 | PHASE2 |
| NCT02955394 | ACTIVE_NOT_RECRUITING | Breast Cancer |
University of Colorado, Denver |
2017-09-21 | PHASE2 |
| NCT04869488 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2021-07-19 | PHASE2 |
| NCT02319837 | ACTIVE_NOT_RECRUITING | Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate |
Pfizer |
2014-12-17 | PHASE3 |
| NCT03300505 | TERMINATED | Prostate Cancer |
University of Michigan Rogel Cancer Center |
2019-05-31 | PHASE1 |
| NCT05549778 | COMPLETED | Castration-resistant Prostate Cancer |
Jiangnan University |
2021-01-06 | PHASE1; PHASE2 |
| NCT02833883 | COMPLETED | Prostate Cancer; Castration Resistant Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2016-07 | PHASE1 |
| NCT03569280 | COMPLETED | Castration-Resistant Prostate Cancer |
Kangpu Biopharmaceuticals, Ltd. |
2019-11-26 | PHASE1 |
| NCT03016741 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostatic Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer; Hormone-Refractory Prostate Cancer |
Northwestern University |
2017-03-31 | PHASE4 |
| NCT02203695 | COMPLETED | Adenocarcinoma of the Prostate |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2015-03-28 | PHASE2 |
| NCT03834493 | COMPLETED | Prostatic Neoplasms |
Merck Sharp & Dohme LLC |
2019-07-28 | PHASE3 |
| NCT02555189 | TERMINATED | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer AJCC v7 |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2015-12-01 | PHASE1; PHASE2 |
| NCT04033328 | TERMINATED | Prostatic Neoplasms |
ORIC Pharmaceuticals |
2019-10-28 | PHASE1 |
| NCT04076059 | ACTIVE_NOT_RECRUITING | Metastatic Hormone Sensitive Prostate Cancer |
Astellas (Beijing) Pharmaceutical R&D Co., Ltd. |
2019-09-11 | PHASE3 |
| NCT04934722 | COMPLETED | Metastatic Hormone-Sensitive Prostate Cancer |
Merck Sharp & Dohme LLC |
2021-05-25 | PHASE3 |
| NCT04191096 | COMPLETED | Metastatic Hormone-Sensitive Prostate Cancer |
Merck Sharp & Dohme LLC |
2020-02-12 | PHASE3 |
| NCT04142060 | TERMINATED | Breast Cancer |
SOLTI Breast Cancer Research Group |
2020-06-01 | PHASE2 |
| NCT03395197 | ACTIVE_NOT_RECRUITING | mCRPC |
Pfizer |
2017-12-18 | PHASE3 |
| NCT01867333 | COMPLETED | Prostate Cancer |
National Cancer Institute (NCI) |
2013-08-12 | PHASE2 |
| NCT04742972 | WITHDRAWN | Prostate Cancer |
Darren Poon |
2021-02-25 | |
| NCT03177187 | TERMINATED | Metastatic Castration Resistant Prostate Cancer |
Institute of Cancer Research, United Kingdom |
2017-11-13 | PHASE1; PHASE2 |
| NCT03753243 | RECRUITING | Prostate Cancer |
Mark Garzotto, MD |
2018-12-03 | PHASE2 |
| NCT03246347 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Prostate Adenocarcinoma |
Wake Forest University Health Sciences |
2017-08-23 | PHASE2 |
| NCT02975934 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
pharmaand GmbH |
2017-06-13 | PHASE3 |
| NCT03751436 | COMPLETED | Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
Roswell Park Cancer Institute |
2019-08-02 | PHASE1 |
| NCT04157088 | TERMINATED | Prostatic Cancer, Castration-Resistant |
Bayer |
2019-12-17 | PHASE2 |
| NCT02640534 | TERMINATED | Cancer of the Prostate; Prostate Cancer |
Swiss Cancer Institute |
2016-06-10 | PHASE2 |
| NCT03336983 | COMPLETED | Prostate Cancer; Bone Metastases |
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
2017-12-01 | PHASE2 |
| NCT03899467 | COMPLETED | Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Suzhou Kintor Pharmaceutical Inc, |
2019-05-30 | PHASE2 |
| NCT03685591 | TERMINATED | Breast Neoplasms; Prostate Neoplasms; Neoplasms, Squamous Cell; Melanoma; Mesothelioma; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell; Liver Neoplasms |
Pfizer |
2018-10-04 | PHASE1 |
| NCT03834519 | COMPLETED | Prostatic Neoplasms |
Merck Sharp & Dohme LLC |
2019-05-02 | PHASE3 |
| NCT04237584 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
MANA RBM |
2020-06-30 | PHASE3 |
| NCT01974765 | COMPLETED | Advanced Epithelial Ovarian; Recurrent Epithelial Ovarian; Fallopian Tube; Primary Peritoneal Carcinoma |
Memorial Sloan Kettering Cancer Center |
2013-11-05 | PHASE2 |
| NCT03314324 | COMPLETED | Metastatic Castrate-resistant Prostate (CRPC) Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2017-11-29 | PHASE2 |
| NCT03123978 | COMPLETED | Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer |
University of California, Davis |
2017-01-09 | PHASE1 |
| NCT01942837 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute |
2013-09-13 | PHASE2 |
| NCT04179396 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
pharmaand GmbH |
2019-12-05 | PHASE1 |
| NCT02903160 | COMPLETED | Prostate Cancer |
Icahn School of Medicine at Mount Sinai |
2017-01-13 | PHASE2 |
| NCT02090114 | COMPLETED | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-08-25 | PHASE2 |
| NCT03305224 | UNKNOWN | Castration-resistant Prostate Cancer; Bone Metastases |
Taro Iguchi, MD, PHD |
2017-10-27 | PHASE2 |
| NCT03437941 | TERMINATED | Metastatic Castration-Resistant Prostate Cancer |
Corcept Therapeutics |
2018-02-20 | PHASE1; PHASE2 |
| NCT04087174 | COMPLETED | Prostate Cancer |
AstraZeneca |
2019-08-05 | PHASE1 |
| NCT04456049 | TERMINATED | COVID-19 Infection |
Ricardo Pereira Mestre |
2020-08-24 | PHASE2 |
| NCT03999515 | TERMINATED | Castration-Resistant Prostate Carcinoma; Double-Negative Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
University of Washington |
2020-04-27 | PHASE2 |
| NCT03531827 | TERMINATED | Metastatic Castration Resistant Prostate Cancer; Prostate Neoplasms |
National Cancer Institute (NCI) |
2019-03-26 | PHASE2 |
| NCT02125084 | COMPLETED | Prostate Cancer |
SCRI Development Innovations, LLC |
2014-10 | PHASE1 |
| NCT03103724 | COMPLETED | Carcinoma Prostate |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2017-03-16 | PHASE2 |
| NCT04475601 | TERMINATED | COVID-19; Corona Virus Infection |
Andreas Josefsson |
2020-07-15 | PHASE2 |
| NCT02058706 | COMPLETED | Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Barbara Ann Karmanos Cancer Institute |
2014-05 | PHASE2 |
| NCT02642913 | COMPLETED | Hepatocellular Carcinoma |
Memorial Sloan Kettering Cancer Center |
2015-12 | PHASE1 |
| NCT03480646 | COMPLETED | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Constellation Pharmaceuticals |
2017-11-15 | PHASE1; PHASE2 |
| NCT03338790 | COMPLETED | Prostate Cancer |
Bristol-Myers Squibb |
2017-12-19 | PHASE2 |
| NCT02740985 | COMPLETED | Advanced Solid Malignancies; Non-Small Cell Lung Cancer (NSCLC); Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC); Colorectal Carcinoma (CRC) |
AstraZeneca |
2016-06-17 | PHASE1 |
| NCT04094519 | COMPLETED | Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2020-01-27 | PHASE1 |
| NCT03770455 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Jodi Layton, MD |
2019-01-25 | PHASE2 |
| NCT03295565 | COMPLETED | Prostate Cancer Metastatic; Metastasis |
The Netherlands Cancer Institute |
2017-05-07 | PHASE2; PHASE3 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT02601014 | COMPLETED | Prostate Cancer; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2016-03-15 | PHASE2 |
| NCT03124615 | UNKNOWN | Prostate Cancer |
Macquarie University, Australia |
2017-05 | PHASE2 |
| NCT03478904 | TERMINATED | Prostate Cancer |
National Cancer Institute (NCI) |
2020-03-10 | PHASE1 |
| NCT03464201 | COMPLETED | Ovarian Cancer |
Grupo Español de Tumores Huérfanos e Infrecuentes |
2018-04-13 | PHASE2 |
| NCT01362374 | COMPLETED | Neoplasms |
Genentech, Inc. |
2011-07-11 | PHASE1 |
| NCT04052204 | TERMINATED | Squamous Cell Carcinoma of the Head and Neck (SCCHN); Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Pfizer |
2019-12-30 | PHASE1; PHASE2 |
| NCT03148795 | COMPLETED | Prostate Cancer |
Pfizer |
2017-07-04 | PHASE2 |
| NCT03829930 | TERMINATED | Prostate Adenocarcinoma |
George Washington University |
2019-05-01 | PHASE1 |
| NCT02508636 | TERMINATED | Prostatic Neoplasms; Pelvic Nodal |
University of California, San Francisco |
2015-12-22 | PHASE2 |
| NCT02799745 | COMPLETED | Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2016-06-09 | PHASE2 |
| NCT03150056 | TERMINATED | Solid Tumours |
GlaxoSmithKline |
2017-07-18 | PHASE1 |
| NCT02489123 | TERMINATED | Ann Arbor Stage I Mantle Cell Lymphoma; Ann Arbor Stage II Mantle Cell Lymphoma; Ann Arbor Stage III Mantle Cell Lymphoma; Ann Arbor Stage IV Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma |
University of Washington |
2015-08-11 | PHASE2 |
| NCT02815033 | COMPLETED | Prostate Cancer Metastatic |
The European Uro-Oncology Group |
2015-07 | PHASE2 |
| NCT02814968 | COMPLETED | Prostate Cancer Metastatic |
The European Uro-Oncology Group |
2015-02 | PHASE2 |
| NCT03002220 | COMPLETED | Prostate Cancer |
MedSIR |
2016-12-21 | PHASE2 |
| NCT02254785 | UNKNOWN | Metastatic Castration-Resistant Prostatic Cancer |
British Columbia Cancer Agency |
2014-10 | PHASE2 |
| NCT02288247 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
Astellas Pharma Europe Ltd. |
2014-12-01 | PHASE3 |
| NCT02588001 | COMPLETED | Prostate Cancer |
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
2015-10-01 | |
| NCT02918968 | COMPLETED | Prostate Cancer |
Astellas Pharma Inc |
2016-11-02 | PHASE4 |
| NCT02885649 | TERMINATED | Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer |
Rutgers, The State University of New Jersey |
2017-12-05 | EARLY_PHASE1 |
| NCT02125357 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
British Columbia Cancer Agency |
2014-09 | PHASE2 |
| NCT02525068 | UNKNOWN | Adenocarcinoma of the Prostate |
Institute of Cancer Research, United Kingdom |
2014-12 | PHASE2 |
| NCT03110588 | WITHDRAWN | Metastatic Prostate Cancer |
University of Alabama at Birmingham |
2018-05-09 | PHASE1 |
| NCT02430480 | COMPLETED | Prostate Cancer |
National Cancer Institute (NCI) |
2015-06-03 | PHASE2 |
| NCT02953860 | COMPLETED | Breast Cancer |
University of Colorado, Denver |
2017-07-06 | PHASE2 |
| NCT03418324 | COMPLETED | Prostate Cancer |
Cedars-Sinai Medical Center |
2018-03-05 | PHASE2 |
| NCT02711956 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Zenith Epigenetics |
2016-12 | PHASE1; PHASE2 |
| NCT02204072 | COMPLETED | Prostatic Neoplasms, Castration-Resistant |
Boehringer Ingelheim |
2014-11-11 | PHASE1 |
| NCT02522715 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v7 |
OHSU Knight Cancer Institute |
2015-08-13 | PHASE1; PHASE2 |
| NCT02215096 | COMPLETED | Neoplasms |
GlaxoSmithKline |
2014-11-13 | PHASE1 |
| NCT03704519 | COMPLETED | Cerebrovascular Circulation |
Bayer |
2018-10-23 | PHASE1 |
| NCT02099864 | COMPLETED | Castration-Resistant Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7 |
OHSU Knight Cancer Institute |
2014-02-05 | PHASE2 |
| NCT02991911 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
MedImmune LLC |
2017-01-06 | PHASE1 |
| NCT02429193 | COMPLETED | Castration-resistant Prostate Cancer |
University Health Network, Toronto |
2016-03 | PHASE2 |
| NCT01875250 | COMPLETED | Prostate Cancer |
National Cancer Institute (NCI) |
2013-07-22 | PHASE2 |
| NCT02288936 | COMPLETED | Hormone-refractory Prostate Cancer |
Spanish Oncology Genito-Urinary Group |
2015-02-05 | PHASE2 |
| NCT03016312 | COMPLETED | Prostatic Neoplasms, Castration-Resistant |
Hoffmann-La Roche |
2017-01-10 | PHASE3 |
| NCT02012296 | COMPLETED | Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
University of Chicago |
2013-12-13 | PHASE1; PHASE2 |
| NCT02987543 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2017-02-06 | PHASE3 |
| NCT02384382 | COMPLETED | Prostate Carcinoma Metastatic to the Bone; Castration Resistant Prostate Cancer |
Pfizer |
2015-11-30 | PHASE2 |
| NCT02278185 | COMPLETED | Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer |
University of Colorado, Denver |
2015-11-11 | PHASE2 |
| NCT02929576 | WITHDRAWN | Breast Cancer |
Pfizer |
2016-09 | PHASE3 |
| NCT02485691 | COMPLETED | Prostate Cancer Metastatic |
Sanofi |
2015-11-09 | PHASE4 |
| NCT02749903 | ACTIVE_NOT_RECRUITING | Salivary Cancer |
Alliance for Clinical Trials in Oncology |
2016-09-14 | PHASE2 |
| NCT02507570 | COMPLETED | Prostate Carcinoma Metastatic to the Bone |
Carolina Research Professionals, LLC |
2015-09-23 | PHASE2 |
| NCT03869762 | TERMINATED | Castration-resistant Prostate Cancer; Metastatic Cancer; Bone Metastases |
Cancer Trials Ireland |
2019-01-09 | PHASE2 |
| NCT02457910 | TERMINATED | Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma |
Vanderbilt-Ingram Cancer Center |
2015-06 | PHASE1; PHASE2 |
| NCT02445976 | COMPLETED | Prostate Cancer |
Innocrin Pharmaceutical |
2015-05 | PHASE2 |
| NCT01949337 | UNKNOWN | Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Alliance for Clinical Trials in Oncology |
2014-01-22 | PHASE3 |
| NCT02286921 | COMPLETED | Castration Resistant Metastatic Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2015-01 | PHASE2 |
| NCT03778047 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
Hinova Pharmaceuticals Inc. |
2018-02-07 | PHASE1 |
| NCT02677896 | COMPLETED | Metastatic Hormone Sensitive Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2016-03-09 | PHASE3 |
| NCT02346578 | COMPLETED | Castration-resistant Prostate Cancer |
Taro Iguchi, MD, PHD |
2014-12 | PHASE2 |
| NCT02407054 | COMPLETED | Prostate Cancer Metastatic |
Eli Lilly and Company |
2015-04-29 | PHASE2 |
| NCT02064582 | COMPLETED | Prostate Cancer |
University of Texas Southwestern Medical Center |
2014-05 | PHASE2 |
| NCT03196388 | UNKNOWN | Prostate Carcinoma |
Fundación Canaria Instituto de Investigación Sanitaria de Canarias |
2017-12-27 | PHASE2 |
| NCT02379390 | TERMINATED | Prostate Cancer Metastatic |
Sanofi |
2015-06-17 | PHASE2 |
| NCT02199197 | COMPLETED | Prostate Cancer |
University of Utah |
2014-06-25 | PHASE2 |
| NCT02453009 | COMPLETED | Prostatic Neoplasms |
Santa Chiara Hospital |
2014-10 | PHASE2 |
| NCT02057939 | COMPLETED | Prostate Cancer |
Duke University |
2014-04 | PHASE2 |
| NCT02491411 | TERMINATED | Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2015-09 | |
| NCT02256111 | COMPLETED | Non-metastatic, Hormone naïve Prostate Cancer |
Duke University |
2015-05-13 | PHASE2 |
| NCT02207504 | COMPLETED | Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute |
2014-08 | PHASE1 |
| NCT02605863 | TERMINATED | Bladder Cancer |
University of Rochester |
2016-01 | PHASE2 |
| NCT01650194 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2012-07-09 | PHASE2 |
| NCT02268175 | COMPLETED | Prostate Adenocarcinoma; Prostate Cancer; High Risk Prostate Cancer |
Dana-Farber Cancer Institute |
2014-10 | PHASE2 |
| NCT02532114 | COMPLETED | Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma |
University of Washington |
2015-12-31 | PHASE1 |
| NCT02607228 | TERMINATED | Metastatic Castrate-Resistant Prostate Cancer |
Gilead Sciences |
2015-12-08 | PHASE1; PHASE2 |
| NCT02528643 | COMPLETED | Advanced Hepatocellular Carcinoma |
Astellas Pharma Global Development, Inc. |
2015-11-09 | PHASE2 |
| NCT02028988 | COMPLETED | Intermediate Risk Prostate Cancer |
Dana-Farber Cancer Institute |
2014-02 | PHASE2 |
| NCT02130700 | COMPLETED | Prostate Cancer |
Innocrin Pharmaceutical |
2014-04 | PHASE2 |
| NCT02300610 | COMPLETED | Bladder Cancer; Carcinoma, Transitional Cell; Renal Pelvis Cancer; Ureter Cancer; Urethra Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2015-02-11 | PHASE1 |
| NCT02685267 | TERMINATED | Prostate Cancer |
Prostate Cancer Clinical Trials Consortium |
2016-02 | PHASE2 |
| NCT01946165 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
2013-10-31 | PHASE2 |
| NCT02023463 | ACTIVE_NOT_RECRUITING | Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer |
Thomas Jefferson University |
2014-04-02 | PHASE1 |
| NCT02225704 | COMPLETED | Prostate Cancer |
Cancer Trials Ireland |
2015-06-03 | PHASE2 |
| NCT01981122 | COMPLETED | Metastatic Prostate Cancer |
Dendreon |
2013-09 | PHASE2 |
| NCT02003924 | COMPLETED | Nonmetastatic Castration-Resistant Prostate Cancer; Prostate Cancer; Cancer of the Prostate |
Pfizer |
2013-10-31 | PHASE3 |
| NCT02124668 | COMPLETED | Castration-Resistant Prostate Cancer; Prostate Cancer |
Astellas Pharma Europe B.V. |
2014-09-23 | PHASE2 |
| NCT02380313 | WITHDRAWN | Cancer |
GlaxoSmithKline |
2015-10 | PHASE1 |
| NCT01534052 | COMPLETED | Castration-Resistant Prostate Cancer (CRPC) |
Astellas Pharma Inc |
2011-10-21 | PHASE2 |
| NCT03297385 | COMPLETED | Prostate Cancer; DNA; Androgen Receptor Abnormal |
The Netherlands Cancer Institute |
2014-08-28 | PHASE2 |
| NCT01927627 | COMPLETED | Adenocarcinoma of the Prostate |
Case Comprehensive Cancer Center |
2013-11-11 | PHASE2 |
| NCT02441517 | TERMINATED | Metastatic Castration Resistant Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2015-10-28 | PHASE4 |
| NCT02091960 | COMPLETED | HER2 Amplified; Advanced Breast Cancer; Human Epidermal Growth Factor Receptor 2 (HER2) |
Astellas Pharma Global Development, Inc. |
2014-09-05 | PHASE2 |
| NCT02215161 | TERMINATED | Castration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7 |
University of California, San Francisco |
2014-09-02 | PHASE2 |
| NCT02676986 | COMPLETED | Primary Breast Cancer ER+ve; Primary Breast Cancer AR+ve TNBN |
Queen Mary University of London |
2015-08-10 | PHASE2 |
| NCT02138383 | COMPLETED | Pancreatic Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2014-05-22 | PHASE1 |
| NCT01995513 | COMPLETED | Prostate Cancer |
Pfizer |
2013-10-22 | PHASE4 |
| NCT02007512 | COMPLETED | Breast Cancer |
Pfizer |
2013-12-16 | PHASE2 |
| NCT02758132 | TERMINATED | Prostate Cancer |
University of Hawaii |
2016-03-01 | PHASE2 |
| NCT02034552 | COMPLETED | Prostatic Neoplasms |
Bayer |
2014-03-07 | PHASE2 |
| NCT02438007 | TERMINATED | Prostate Cancer |
LTN PHARMACEUTICALS, INC. |
2015-06 | PHASE3 |
| NCT02500901 | TERMINATED | Metastatic Prostate Cancer |
Paul Mathew, MD |
2016-03 | PHASE1 |
| NCT02116582 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Astellas Pharma Europe B.V. |
2014-05-23 | PHASE4 |
| NCT01977651 | COMPLETED | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Astellas Pharma Global Development, Inc. |
2013-09-25 | PHASE4 |
| NCT02130947 | WITHDRAWN | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
UNC Lineberger Comprehensive Cancer Center |
2014-04 | |
| NCT01597193 | COMPLETED | Breast Cancer |
Pfizer |
2012-04-30 | PHASE1 |
| NCT01981707 | TERMINATED | Castration-resistant Prostate Cancer |
University Hospital, Grenoble |
2013-12 | PHASE2; PHASE3 |
| NCT02294461 | COMPLETED | Progressive Metastatic Prostate Cancer |
Astellas Pharma Inc |
2014-04-23 | PHASE3 |
| NCT01889238 | COMPLETED | Advanced, Androgen Receptor Positive Triple Negative Breast Cancer |
Pfizer |
2013-06-12 | PHASE2 |
| NCT01664923 | COMPLETED | Prostate Cancer |
Pfizer |
2012-08 | PHASE2 |
| NCT02159690 | WITHDRAWN | Prostate Cancer; Localized Prostate Cancer |
Kenneth Pienta, MD |
2014-09 | PHASE2 |
| NCT01288911 | COMPLETED | Prostatic Neoplasms |
Astellas Pharma Inc |
2011-03-22 | PHASE2 |
| NCT01663415 | WITHDRAWN | Metastatic Castration-Resistant Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2012-08 | PHASE2 |
| NCT02138162 | COMPLETED | Severe Hepatic Impairment; Normal Hepatic Function |
Astellas Pharma Europe B.V. |
2013-08 | PHASE1 |
| NCT02225093 | COMPLETED | Pharmacokinetics of Dextromethorphan; Pharmacokinetics of Caffeine; Prostate Cancer |
Astellas Pharma Europe B.V. |
2013-10-02 | PHASE1 |
| NCT01547299 | COMPLETED | Prostate Cancer |
Pfizer |
2012-03-31 | PHASE2 |
| NCT01902251 | COMPLETED | Prostate Cancer; Pharmacokinetics of Enzalutamide |
Astellas Pharma Europe B.V. |
2012-11 | PHASE1 |
| NCT01212991 | COMPLETED | Prostate Cancer |
Pfizer |
2010-09-16 | PHASE3 |
| NCT02138799 | COMPLETED | Drug-Drug Interaction (DDI); Healthy Subjects; Pharmacokinetics of Enzalutamide |
Astellas Pharma Europe B.V. |
2013-07 | PHASE1 |
| NCT01911741 | COMPLETED | Healthy Subjects; Castration Resistant Prostate Cancer (CRPC); Relative Bioavailability; MDV3100 |
Astellas Pharma Europe B.V. |
2012-11 | PHASE1 |
| NCT01302041 | COMPLETED | Prostate Cancer |
Astellas Pharma Inc |
2011-05-06 | PHASE2 |
| NCT01091103 | COMPLETED | Metastatic Progressive Castration-resistant Prostate Cancer |
Pfizer |
2010-02-18 | PHASE2 |
| NCT00974311 | COMPLETED | Castration-Resistant Prostate Cancer |
Pfizer |
2009-09-30 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-08-31)
Check the
MDV3100 (Enzalutamide)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- MDV3100 (Enzalutamide) Mechanism of Action: Androgen Receptor Inhibition in Prostate Cancer Cells Research
- MDV3100 (Enzalutamide) Working Concentration | Cell Culture | Treatment
- MDV3100 (Enzalutamide) Solubility in DMSO
- MDV3100 (Enzalutamide) Stock Solution
- MDV3100 (Enzalutamide) Storage
- MDV3100 (Enzalutamide) Stability
- MDV3100 (Enzalutamide) Combination Database
- MDV3100 (Enzalutamide) Molecular Weight
- MDV3100 (Enzalutamide) SMILES
- MDV3100 (Enzalutamide) CAS Number
- MDV3100 (Enzalutamide) Chemical Structure (2D and 3D)
- MDV3100 (Enzalutamide) IC50 for Cell-based and Cell-free Assays
- MDV3100 (Enzalutamide) Sigma (AMBH2D6F1828)?? Try a better option.
- MDV3100 (Enzalutamide) MedChemExpress (HY-70002)?? Try a better option.
- MDV3100 (Enzalutamide) Cayman (11596)?? Try a better option.
- MDV3100 (Enzalutamide) Abmole (M1839)?? Try a better option.
- MDV3100 (Enzalutamide) STEMCELL (100-1650)?? Try a better option.
- MDV3100 (Enzalutamide) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.